Discover a New Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

• Review safety, closing, and administration of the agent,
• Discuss efficacy data from a key clinical trial for this therapy,
• Address the challenges of treating some patients with triple-class refractory multiple myeloma

Presenter:  Cristina Gasparetto, MD, Director of Multiple Myeloma Program, Duke University Medical Center, Durham, NC

Date: Thursday June 24, 2021 
Time: 12:00 PM ET
 

IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.

This webinar is sponsored by: